Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment

Abstract

Purpose: To evaluate the safety and efficacy of miglustat in patients with G M2 gangliosidosis. Methods: A randomized, multicenter, openlabel, 12-month study involving patients aged 18 years or older, randomized 2:1 to miglustat (200 mg TID) or "no miglustat treatment." This study was followed by 24 months of extended treatment during which all patients received miglustat. Primary efficacy endpoints were change in eight measures of isometric muscle strength in the limbs and isometric grip strength, evaluated at baseline, and months 12 and 36. Secondary efficacy endpoints included gait, balance, disability, and other neurological assessments. Safety evaluations included adverse event reporting. Results: Thirty patients (67% male, age range 18 -56 years) with late-onset Tay-Sachs disease were enrolled; 20 were randomized to miglustat and 10 to "no miglustat treatment." Muscle and grip strength generally decreased over the study period. No differences were observed between the two groups in any efficacy measure, either during the 12-month randomized phase or the full 36 months. The most common treatment-related adverse events were decrease in weight and diarrhea. Conclusion: Miglustat treatment was not shown to lead to measurable benefits in this cohort of patients with late-onset Tay-Sachs disease. The observed safety profile was consistent with that of the approved dose (100 mg TID) in type 1 Gaucher disease. Genet Med 2009:11(6):425-433.

Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis

“…In these experiments, the restoration of enzyme activities and reduction of substrates accumulated in the brains of disease model animals were demonstrated, although the effectiveness varied among diseases. On the other hand, experimental and clinical approaches, including bone marrow transplantation, 34 substrate deprivation therapy, 35,36 normal gene transfer, 37 and stem cell therapy, 38 have been developed to treat…”

Development of targeted therapies for Parkinson's disease and related synucleinopathies

“…The lack of effect on glycolipid levels may likely be due to the inhibitory effect of the drug on the enzyme. The basis for its impact on survival is not clear, but may be to date ( 54,55 ) ( 56 ). Although a benefi t of miglustat can be observed in some animal models of neuronal glycophingolipidoses, its clinical effects in these disorders has been very limited at best.…”

Rethinking fatigue in Gaucher disease

“…Fifteen manuscripts were published in English [11,[13][14][15][16][17][18][19][20][21][22][23][24][25][26], and the remaining 4 articles were published in German [27], French [28], Hungarian [29], and Danish [30]. For the articles published in German, French, Hungarian, or Danish, English-language abstracts were available and reviewed.…”